Could mounjaro help a rare fat disorder? new trial aims to find out

NCT ID NCT07091734

Recruiting now Disease control Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests whether tirzepatide (Mounjaro), a drug already approved for diabetes and weight loss, can improve blood sugar and lower triglycerides in people with partial lipodystrophy—a rare condition where the body loses fat tissue. Researchers will compare tirzepatide plus usual care against usual care alone in 32 adults over 24 weeks. The goal is to see if the drug helps by reducing calorie intake.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tirzepatide (Mounjaro)
What this could lead to: If it works, this could offer a new way to manage diabetes and high triglycerides in people with partial lipodystrophy, potentially improving metabolic health.
What could go wrong: This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. Tirzepatide can cause gastrointestinal side effects, and it's not yet proven for this specific condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL PARTIAL LIPODYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired partial lipodystrophy familial partial lipodystrophy partial lipodystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIPODYSTROPHY, PARTIAL

Contacts and locations

Locations

University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.